nach oben

Erschienen in:

01.02.2015 | Guideline

Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy

verfasst von: Kenji Ishikura, Shinsuke Matsumoto, Mayumi Sako, Kazushi Tsuruga, Koichi Nakanishi, Koichi Kamei, Hiroshi Saito, Shuichiro Fujinaga, Yuko Hamasaki, Hiroko Chikamoto, Yasufumi Ohtsuka, Yasuhiro Komatsu, Toshiyuki Ohta, Takuhito Nagai, Hiroshi Kaito, Shuji Kondo, Yohei Ikezumi, Seiji Tanaka, Yoshitsugu Kaku, Kazumoto Iijima

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Excerpt

Nephrotic syndrome is a disorder characterized by severe proteinuria, hypoproteinemia, and generalized edema resulting from damage to the glomerular basement membrane. In Western countries, nephrotic syndrome affects 2 of 100,000 children per year [1]. In Japan, approximately 1,300 new cases per year of pediatric nephrotic syndrome are reported to the Medical Aid for Specific Chronic Disease of Children and the disease develops in 5 of 100,000 children per year. Approximately 90 % of the cases of pediatric nephrotic syndrome are idiopathic, or of unknown cause. The first-line treatment for an initial episode of pediatric idiopathic nephrotic syndrome is oral steroid therapy, which leads to remission in approximately 80 % of cases (steroid-sensitive nephrotic syndrome) [2]. However, 80 % of children with steroid-sensitive nephrotic syndrome experience one or more relapses, [3] and 50 % of these children have frequent relapses [4]. Those with frequently relapsing nephrotic syndrome are prone to suffer steroid-induced side effects such as obesity, growth impairment, hypertension, diabetes mellitus, osteoporosis, and adrenal insufficiency. Many cases of steroid-resistant nephrotic syndrome, where steroids are ineffective, progress to renal failure. …

Schlesinger ER, Sultz HA, Mosher WE, Feldman JG. The nephrotic syndrome. Its incidence and implications for the community. Am J Dis Child. 1968;116:623–32.PubMed

Koskimies O, Vilska J, Rapola J, Hallman N. Long-term outcome of primary nephrotic syndrome. Arch Dis Child. 1982;57:544–8.PubMedCentralPubMed

Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol. 1997;8:769–76.PubMed

Arbeitsgemeinschaft für Pädiatrische Nephrologie. Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl J Med. 1982;306:451–4

Fukui T, Yoshida M, Yamaguchi N. Minds Handbook for Guideline Development 2007. Tokyo: IGAKU-SHOIN Ltd.; 2007 (article in Japanese).

Lohr KN. Clinical practice guidelines: directions for a new program. Washington, DC: National Academy Press. Field MJ; 1990.

The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr. 1981;98:561–4.

International Study of Kidney Disease in Children. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978;13:159–65

Gulati S, Sharma AP, Sharma RK, Gupta A, Gupta RK. Do current recommendations for kidney biopsy in nephrotic syndrome need modifications? Pediatr Nephrol. 2002;17:404–8.PubMed

10.

Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis. 1998;32:72–9.PubMed

11.

Kim JH, Park SJ, Yoon SJ, Lim BJ, Jeong HJ, Lee JS, Kim PK, Shin JI. Predictive factors for ciclosporin-associated nephrotoxicity in children with minimal change nephrotic syndrome. J Clin Pathol. 2011;64:516–9.PubMed

12.

Kengne-Wafo S, Massella L, Diomedi-Camassei F, Gianviti A, Vivarelli M, Greco M, Stringini GR, Emma F. Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome. Clin J Am Soc Nephrol. 2009;4:1409–16.PubMed

13.

Iijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, Yoshikawa N. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int. 2002;61:1801–5.PubMed

14.

Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y. Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome. Arch Dis Child. 2006;91:666–70.PubMedCentralPubMed

15.

Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, Nakanishi K, Yata N, Honda M. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 2008;73:1167–73.PubMed

16.

Ishikura K, Yoshikawa N, Hattori S, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Yata N, Ando T, Honda M, for Japanese Study Group of Renal Disease in Children. Treatment with microemulsified cyclosporine in children with frequently relapsing nephrotic syndrome. Nephrol Dial Transplant. 2010;25:3956–62.

17.

Morgan C, Sis B, Pinsk M, Yiu V. Renal interstitial fibrosis in children treated with FK506 for nephrotic syndrome. Nephrol Dial Transplant. 2011;26:2860–5.PubMed

18.

Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of “Arbeitsgemeinschaft für Pädiatrische Nephrologie”. Lancet. 1979;1:401–3.

19.

Ueda N, Chihara M, Kawaguchi S, Niinomi Y, Nonoda T, Matsumoto J, Ohnishi M, Yasaki T. Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. J Pediatr. 1988;112:122–6.PubMed

20.

Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft for Pediatrische Nephrologie. Eur J Pediatr. 1993;152:357–61.PubMed

21.

Ksiazek J, Wyszyńska T. Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Acta Paediatr. 1995;84:889–93.PubMed

22.

Bagga A, Hari P, Srivastava RN. Prolonged versus standard prednisolone therapy for initial episode of nephrotic syndrome. Pediatr Nephrol. 1999;13:824–7.PubMed

23.

Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, Hayashi S, Ohta K, Momoi T, Ohshima Y, Suganuma N, Mayumi M. West Japan Cooperative Study Group of Kidney Disease in Children. A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis. 2003;41:1155–62.PubMed

24.

Norero C, Delucchi A, Lagos E, Rosati P. Initial therapy of primary nephrotic syndrome in children: evaluation in a period of 18 months of two prednisone treatment schedules. Chilean Co-operative Group of Study of Nephrotic Syndrome in Children. Rev Med Chil. 1996;124:567–72 (article in Spanish).PubMed

25.

Yoshikawa N, Ito H, Takekoshi Y, Honda M, Awazu M, Iijima K, Nakamura H, Seino Y, Takeda N, Hattori S, Matsuda I. Standard versus long-term prednisolone with Sairei-to for initial therapy in childhood steroid-responsive nephrotic syndrome: a prospective controlled study. Jpn J Nephrol. 1998;40:587–90 (article in Japanese).

26.

Lande MB, Gullion C, Hogg RJ, Gauthier B, Shah B, Leonard MB, Bonilla-Felix M, Nash M, Roy S 3rd, Strife CF, Arbus G. Long versus standard initial steroid therapy for children with the nephrotic syndromeA report from the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol. 2003;18:342–6.PubMed

27.

Hirano D, Nishizaki N, Kanai H, Hara S, Ohtomo Y, Umino D, Fujinaga S. Long-term outcome of children treated with the ISKDC regimen for the first episode of INS. Jpn J Nephrol. 2010;52:1029–36 (article in Japanese).

28.

Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2007;(4):CD001533.

29.

Ekka BK, Bagga A, Srivastava RN. Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr Nephrol. 1997;11(5):597–9.PubMed

30.

Hoyer PF, Brodeh J. Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial. J Am Soc Nephrol. 2006;17:1151–7.PubMed

31.

Hayashi M, Kimura N, Fukatsu A. Combined effect of cyclosporin and prednisolone for minimal change nephrotic syndrome: comparison with prednisolone therapy. Jpn J Nephrol. 2008;50:581–7 (article in Japanese).

32.

Yoshikawa N, Ito H. Kampo medicine for pediatric renal disease: nephrotic syndrome. J Tradit Sino-Jpn Med. 1991;12:24–7 (article in Japanese).

33.

Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev. 2008;(1):CD002290.

34.

Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zacchello G, Confalonieri R, Altieri P. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant. 1993;8:1326–32.PubMed

35.

Niaudet P, Broyer M, Habib R. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. Clin Nephrol. 1991;35 Suppl1:S31–6.

36.

El-Husseini A, El-Basuony F, Mahmoud I, Sheashaa H, Sabry A, Hassan R, Taha N, Hassan N, Sayed-Ahmad N, Sobh M. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrol Dial Transplant. 2005;20:2433–8.PubMed

37.

Kitano Y, Yoshikawa N, Tanaka R, Nakamura H, Ninomiya M, Ito H. Ciclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 1990;4(5):474–7.PubMed

38.

Tanaka R, Yoshikawa N, Kitano Y, Ito H, Nakamura H. Long-term ciclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 1993;7:249–52.PubMed

39.

Inoue Y, Iijima K, Nakamura H, Yoshikawa N. Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 1999;13(1):33–8.PubMed

40.

Ishikura K, Yoshikawa N, Nakazato H, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ito S, Yata N, Ando T, Honda M. Japanese Study Group of Renal Disease in Children. Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children. Clin J Am Soc Nephrol. 2012;7:1576–83.PubMedCentralPubMed

41.

Kemper MJ, Kuwertz-Broeking E, Bulla M, Mueller-Wiefel DE, Neuhaus TJ. Recurrence of severe steroid dependency in cyclosporin A-treated childhood idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2004;19:1136–41.PubMed

42.

Niaudet P, Reigneau O, Humbert H. A pharmacokinetic study of Neoral in childhood steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2001;16:154–5.PubMed

43.

David-Neto E, Araujo LM, Brito ZM, Alves CF, Lemos FC, Yagyu EM, Nahas WC, Ianhez LE. Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve. Am J Transplant. 2002;2:546–50.PubMed

44.

Filler G. How should microemulsified cyclosporine A (Neoral) therapy in patients with nephrotic syndrome be monitored. Nephrol Dial Transplant. 2005;20:1032–4.PubMed

45.

Suzuki K, Oki E, Tsuruga K, Aizawa-Yashiro T, Ito E, Tanaka H. Benefits of once-daily administration of cyclosporine a for children with steroid-dependent, relapsing nephrotic syndrome. Tohoku J Exp Med. 2010;220:183–6.PubMed

46.

Fujinaga S, Hirano D, Murakami H, Ohtomo Y, Shimizu T, Kaneko K. Nephrotoxicity of once-daily cyclosporine A in minimal change nephrotic syndrome. Pediatr Nephrol. 2012;27:671–4.PubMed

47.

Barratt TM, Soothill JF. Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet. 1970;2:479–82.PubMed

48.

International Study of Kidney Disease in Children (ISKDC). Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet. 1974;2:423–7.

49.

Barratt TM, Cameron JS, Chantler C, Ogg CS, Soothill JF. Comparative trial of 2 weeks and 8 weeks cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Arch Dis Child. 1973;48:286–90.PubMedCentralPubMed

50.

Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. Arch Dis Child 1987;62:1102–6.

51.

Ueda N, Kuno K, Ito S. Eight and 12 week courses of cyclophosphamide in nephrotic syndrome. Arch Dis Child. 1990;65:1147–50.PubMedCentralPubMed

52.

Kyrieleis HA, Levtchenko EN, Wetzels JF. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am J Kidney Dis. 2007;49:592–7.PubMed

53.

Cammas B, Harambat J, Bertholet-Thomas A, Bouissou F, Morin D, Guigonis V, Bendeddouche S, Afroukh-Hacini N, Cochat P, Llanas B, Decramer S, Ranchin B. Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2011;26:178–84.PubMed

54.

Vester U, Kranz B, Zimmermann S, Hoyer PF. Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol. 2003;18:661–4.PubMed

55.

Azib S, Macher MA, Kwon T, Dechartres A, Alberti C, Loirat C, Deschênes G, Baudouin V. Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26:927–32.PubMed

56.

Srivastava RN, Agarwal RK, Choudhry VP, Moudgil A, Bhuyan UN, Sunderam KR. Cyclophosphamide therapy in frequently relapsing nephrotic syndrome with and without steroid dependence. Int J Pediatr Nephrol. 1985;6:245–50.PubMed

57.

Zagury A, de Oliveira AL, de Moraes CA, de Araujo Montalvão JA, Novaes RH, de Sá VM, Monteiro de Carvalho Dde B, Matuck T. Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26:915–20.

58.

Garin EH, Pryor ND, Fennell RS 3rd, Richard GA. Pattern of response to prednisone in idiopathic, minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy. J Pediatr. 1978;92:304–8.PubMed

59.

Kemper MJ, Altrogge H, Ludwig K, Timmermann K, Müller-Wiefel DE. Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2000;14:772–5.PubMed

60.

Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol. 2001;16:271–82.PubMed

61.

Siegel NJ, Gaudio KM, Krassner LS, McDonald BM, Anderson FP, Kashgarian M. Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment. Kidney Int. 1981;19:454–9.PubMed

62.

Tejani A, Phadke K, Nicastri A, Adamson O, Chen CK, Trachtman H, Tejani C. Efficacy of cyclophosphamide in steroid-sensitive childhood nephrotic syndrome with different morphological lesions. Nephron. 1985;41:170–3.PubMed

63.

Gulati S, Pokhariyal S, Sharma RK, Elhence R, Kher V, Pandey CM, Gupta A. Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome. Nephrol Dial Transplant. 2001;16:2013–7.PubMed

64.

Bircan Z, Kara B. Intravenous cyclophosphamide is the drug of choice for steroid dependent nephrotic syndrome. Pediatr Int. 2003;45:65–7.PubMed

65.

Prasad N, Gulati S, Sharma RK, Singh U, Ahmed M. Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2004;19:494–8.PubMed

66.

Donia AF, Gazareen SH, Ahmed HA, Moustafa FE, Shoeib AA, Ismail AM, Khamis S, Sobh MA. Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid-dependent children. Nephrol Dial Transplant. 2003;18:2054–8.PubMed

67.

Wetzels JF. Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis. Neth J Med. 2004;62:347–52.PubMed

68.

Hodson EM, Craig JC, Willis NS. Evidence-based management of steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2005;20:1523–30.PubMed

69.

Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 1988;259:2123–5.PubMed

70.

Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, Tanizawa T, Wada H, Maki S. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000;58:317–24.PubMed

71.

Kawasaki Y, Hosoya M, Kobayashi S, Ohara S, Onishi N, Takahashi A, Isome M, Suzuki H. Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome. Nephrol Dial Transplant. 2005;20(10):2243–7.PubMed

72.

Kawasaki Y, Takano K, Isome M, Suzuki J, Suyama K, Kanno H, Fujiki T, Suzuki H, Hosoya M. Efficacy of single dose of oral mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome. J Nephrol. 2007;20:52–6.PubMed

73.

Fujieda M, Ishihara M, Morita T, Hayashi A, Utsunomiya Y, Ohta T, Sakano T, Wakiguchi H. Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome. Clin Nephrol. 2008;69:179–84.PubMed

74.

Ohtomo Y, Fujinaga S, Takada M, Murakami H, Akashi S, Shimizu T, Kaneko K, Yamashiro Y. High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephrotic syndrome with cyclosporin nephrotoxicity. Pediatr Nephrol. 2005;20:1744–9.PubMed

75.

Fujinaga S, Hirano D, Nishizaki N, Someya T, Ohtomo Y, Ohtsuka Y, Shimizu T, Kaneko K. Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration. Pediatr Nephrol. 2011;26:479–83.PubMed

76.

Goto M, Ikeda M, Hataya H, Ishikura K, Hamasaki Y, Honda M. Beneficial and adverse effects of high-dosage MZR therapy in the management of children with frequently relapsing nephrotic syndrome. Jpn J Nephrol. 2006;48:365–70 (article in Japanese).

77.

Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008;23:1269–79.

78.

Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321–8.PubMed

79.

Prytuła A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, Ognjanovic M, Filler G, Smith G, Tullus K. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010;25:461–8.PubMed

80.

Sellier-Leclerc AL, Macher MA, Loirat C, Guérin V, Watier H, Peuchmaur M, Baudouin V, Deschênes G. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010;25:1109–15.PubMed

81.

Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010;5:2207–12.PubMedCentralPubMed

82.

Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, Shimizu T. Kaneko K.ingle infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010;25:539–44.PubMed

83.

Sinha A, Bagga A, Gulati A, Hari P. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2012;27:235–41.PubMed

84.

Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6:1308–15.PubMedCentralPubMed

85.

Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, Dötsch J. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012;27:1910–5.PubMed

86.

Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guérin V, Lapillonne H, Deschênes G, Ulinski T. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood–follow-up after CD19 recovery. Nephrol Dial Transplant. 2012;27:1083–9.PubMed

87.

Hiramoto R, Matsumoto S, Eguchi H, Miyoshi Y, Komori I, Akikusa B, Shibata S, Kamei K. Iijima K A case of a 7-year-old boy with steroid-dependent nephrotic syndrome who developed severe neutropenia three months after the administration of rituximab. Japanese Journal of Pediatric Nephrology. 2009;22:97–101 (article in Japanese).

88.

Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, Higuchi M, Matsuoka K. Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol. 2013;28:145–9PubMed

89.

Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47:187–98.PubMed

90.

Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Deschênes G. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol. 2009;24:1753–5.PubMed

91.

Ardelean DS, Gonska T, Wires S, Cutz E, Griffiths A, Harvey E, Tse SM, Benseler SM. Severe ulcerative colitis after rituximab therapy. Pediatrics. 2010;126:e243–6.PubMed

92.

Bagga A, Hari P, Moudgil A, Jordan SC. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis. 2003;42:1114–20.PubMed

93.

Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N, Trachtman H, Swinford R. Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol. 2006;1:1173–8.PubMed

94.

Afzal K, Bagga A, Menon S, Hari P, Jordan SC. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2007;22:2059–65.PubMed

95.

Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol. 2003;18:833–7.PubMed

96.

Ulinski T, Dubourg L, Saïd MH, Parchoux B, Ranchin B, Cochat P. Switch from cyclosporine A to mycophenolate mofetil in nephrotic children. Pediatr Nephrol. 2005;20:482–5.PubMed

97.

Mendizábal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol. 2005;20:914–9.PubMed

98.

Okada M, Sugimoto K, Yagi K, Yanagida H, Tabata N, Takemura T. Mycophenolate mofetil therapy for children with intractable nephrotic syndrome. Pediatr Int. 2007;49:933–7.PubMed

99.

Fujinaga S, Ohtomo Y, Umino D, Takemoto M, Shimizu T, Yamashiro Y, Kaneko K. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol. 2007;22:71–6.PubMed

100.

Fujinaga S, Ohtomo Y, Hirano D, Nishizaki N, Someya T, Ohtsuka Y, Kaneko K, Shimizu T. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clin Nephrol. 2009;72:268–73.PubMed

101.

Gellermann J, Querfeld U. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol. 2004;19:101–4.PubMed

102.

Dorresteijn EM. Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol. 2008;23:2013–20.PubMed

103.

Novak I, Frank R, Vento S, Vergara M, Gauthier B, Trachtman H. Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2005;20:1265–8.PubMed

104.

Al-Akash S, Al-Makdama A. Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome. Ann Saudi Med. 2005;25:380–4.PubMed

105.

Baudouin V, Alberti C, Lapeyraque AL, Bensman A, André JL, Broux F, Cailliez M, Decramer S, Niaudet P, Deschênes G, Jacqz-Aigrain E, Loirat C. Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. Pediatr Nephrol. 2012;27:389–96.PubMed

106.

Dittrich K, Knerr I, Rascher W, Dötsch J. Transient insulin-dependent diabetes mellitus in children with steroid-dependent idiopathic nephrotic syndrome during tacrolimus treatment. Pediatr Nephrol. 2006;21:958–61.PubMed

107.

Sinha MD, MacLeod R, Rigby E, Clark AG. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant. 2006;21:1848–54.PubMed

108.

Dötsch J, Dittrich K, Plank C, Rascher W. Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A. Nephrol Dial Transplant. 2006;21:1761–3.PubMed

109.

Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant. 2007;22:2183–93.PubMed

110.

Mori K, Honda M, Ikeda M. Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19:1232–6.PubMed

111.

Hamasaki Y, Yoshikawa N, Hattori S, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ishikura K, Yata N, Kaneko T, Honda M. Japanese Study Group of Renal Disease. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2009;24:2177–85.PubMed

112.

Bagga A, Mudigoudar BD, Hari P, Vasudev V. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19:45–50.PubMed

113.

Karle SM, Uetz B, Ronner V, Glaeser L, Hildebrandt F, Fuchshuber A. Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2002;13:388–93.PubMed

114.

Weber S, Gribouval O, Esquivel EL, Morinière V, Tête MJ, Legendre C, Niaudet P, Antignac C. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int. 2004;66:571–9.PubMed

115.

Chernin G, Heeringa SF, Gbadegesin R, Liu J, Hinkes BG, Vlangos CN, Vega-Warner V, Hildebrandt F. Low prevalence of NPHS2 mutations in African American children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2008;23:1455–60.PubMed

116.

Santín S, Bullich G, Tazón-Vega B, García-Maset R, Giménez I, Silva I, Ruíz P, Ballarín J, Torra R, Ars E. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol. 2011;6:1139–48.PubMedCentralPubMed

117.

Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F, Pasquali S, Castellani A, Della Casa Alberighi O. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993;43:1377–84.PubMed

118.

Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 1996;7:56–63.PubMed

119.

Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis. 2009;53:760–9.PubMed

120.

Mahmoud I, Basuni F, Sabry A, El-Husseini A, Hassan N, Ahmad NS, Elbaz M, Moustafa F, Sobh M. Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2005;20:735–42.PubMed

121.

Hamasaki Y, Yoshikawa N, Nakazato H, Sasaki S, Iijima K, Nakanishi K, Matsuyama T, Ishikura K, Ito S, Kaneko T, Honda M, for Japanese Study Group of Renal Disease in Children. Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Pediatr Nephrol. 2013;28:765–71.

122.

Ingulli E, Singh A, Baqi N, Ahmad H, Moazami S, Tejani A. Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. J Am Soc Nephrol. 1995;5:1820–5.PubMed

123.

Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999;56:2220–6.PubMed

124.

Heering P, Braun N, Müllejans R, Ivens K, Zäuner I, Fünfstück R, Keller F, Krämer BK, Schollmeyer P, Risler T, Grabensee B. German Collaborative Glomerulonephritis Study Group Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis. 2004;43:10–8.

125.

Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr. 1994;125:981–6.PubMed

126.

Sako M, Iijima K, Saito M, Ohashi Y, Yoshikawa N. Cyclosporine C2 monitaring for frequently relapsing nephrotic syndrome in children: a randomized controlled trial. Jpn J Nephrol. 2012;54:253 (article in Japanese).

127.

Naito M, Takei T, Eguchi A, Uchida K, Tsuchiya K, Nitta K. Monitoring of blood cyclosporine concentration in steroid-resistant nephrotic syndrome. Intern Med. 2008;47:1567–72.PubMed

128.

Ishikura K, Ikeda M, Hamasaki Y, Hataya H, Nishimura G, Hiramoto R, Honda M. Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome. Nephrol Dial Transplant. 2008;23:2531–2536.PubMed

129.

Segarra A, Vila J, Pou L, Majó J, Arbós A, Quiles T, Piera LL. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant. 2002;17:655–62.PubMed

130.

Waldo FB, Benfield MR, Kohaut EC. Therapy of focal and segmental glomerulosclerosis with methylprednisolone, cyclosporine A, and prednisone. Pediatr Nephrol. 1998;12:397–400.PubMed

131.

Yorgin PD, Krasher J, Al-Uzri AY. Pulse methylprednisolone treatment of idiopathic steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2001;16:245–50.PubMed

132.

Shenoy M, Plant ND, Lewis MA, Bradbury MG, Lennon R, Webb NJ. Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome. Pediatr Nephrol. 2010;25:899–903.PubMed

133.

Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1996;10:590–3.PubMed

134.

Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W. Arbeits-gemeinschaft für Pädiatrische Nephrologie. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol. 2008;23:1483–93.PubMedCentralPubMed

135.

Yi Z, Li Z, Wu XC, He QN, Dang XQ, He XJ. Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol. 2006;21:967–72.PubMed

136.

Paik KH, Lee BH, Cho HY, Kang HG, Ha IS, Cheong HI, Jin DK, Moon KC, Choi Y. Primary focal segmental glomerular sclerosis in children: clinical course and prognosis. Pediatr Nephrol. 2007;22:389–95.PubMed

137.

Troyanov S. Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16:1061–8.PubMed

138.

Martinelli R, Okumura AS, Pereira LJ, Rocha H. Primary focal segmental glomerulosclerosis in children: prognostic factors. Pediatr Nephrol. 2001;16:658–61.PubMed

139.

Abeyagunawardena AS, Sebire NJ, Risdon RA, Dillon MJ, Rees L, Van’t Hoff W, Kumarasiri PV, Trompeter RS. Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol. 2007;22:215–21.PubMed

140.

Crenshaw G, Bigler S, Salem M, Crook ED. Focal segmental glomerulosclerosis in African Americans: effects of steroids and angiotensin converting enzyme inhibitors. Am J Med Sci. 2000;319:320–5.PubMed

141.

Stiles KP, Abbott KC, Welch PG, Yuan CM. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic. Clin Nephrol. 2001;56:89–95.PubMed

142.

Muso E, Mune M, Yorioka N, Nishizawa Y, Hirano T, Hattori M, Sugiyama S, Watanabe T, Kimura K, Yokoyama H, Sato H, Saito T. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol. 2007;67:341–4.PubMed

143.

Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Takemura T, Miki S, Kuwahara T, Takamitsu Y, Tsubakihara Y; Kansai FGS, LDL Apheresis Treatment (K-FLAT) Study Group. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron. 2001;89:408–15.

144.

Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Miki S, Kuwahara T, Takamitsu Y, Takemura T, Tsubakihara Y, Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kidney Int Suppl. 1999;71:122–5.

145.

Tojo K, Sakai S, Miyahara T. Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Nihon Jinzo Gakkai Shi. 1988;30:1153–60.PubMed

146.

Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis. 2003;42:1121–30.PubMed

147.

Yokoyama K, Sakai S, Sigematsu T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T. LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. Clin Nephrol. 1998;50:1–7.PubMed

148.

Okada T, Takahashi H, Ogura M, Nakao T, Shimizu T. Complete remission of steroid-resistant minimal-change nephrotic syndrome by cyclosporin after additional low-density lipoprotein apheresis treatment. Jpn J Nephrol. 1996;38:46–51 (article IN Japanese).

149.

Franke D, Zimmering M, Wolfish N, Ehrich JH, Filler G. Treatment of FSGS with plasma exchange and immunadsorption. Pediatr Nephrol. 2000;14:965–9.PubMed

150.

Feld SM, Figueroa P, Savin V, Nast CC, Sharma R, Sharma M, Hirschberg R, Adler SG. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis. 1998;32:230–7.PubMed

151.

Mitwalli AH. Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant. 1998;13:1524–8.PubMed

152.

Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, Benetti E, Murtas C, Messina G, Massella L, Porcellini MG, Montagna M, Regazzi M, Scolari F, Ghiggeri GM. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol. 2012;23:1117–24.PubMedCentralPubMed

153.

Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19:281–7.PubMed

154.

Bhimma R, Adhikari M, Asharam K, Connolly C. Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol. 2006;26:544–51.PubMed

155.

Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburaj VP. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant. 2008;23:910–3.PubMed

156.

Butani L, Ramsamooj R. Experience with tacrolimus in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2009;24:1517–23.PubMedCentralPubMed

157.

Roberti I, Vyas S. Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol. 2010;25:1117–24.PubMed

158.

Pandirikkal VB, Jain M, Gulati S. Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome. Pediatr Nephrol. 2007;22:298–300.

159.

de Mello VR, Rodrigues MT, Mastrocinque TH, Martins SP, de Andrade OV, Guidoni EB, Scheffer DK, Martini Filho D, Toporovski J, Benini V. Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome. Pediatr Nephrol. 2010;25:453–60.PubMed

160.

Li Z, Duan C, He J, Wu T, Xun M, Zhang Y, Yin Y. Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2010;25:883–8.PubMed

161.

Gargah TT, Lakhoua MR. Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome. J Nephrol. 2011;24:203–7.PubMed

162.

Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento SM, McMahan JL, Siegel N, D’Agati VD, Friedman AL. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011;80:868–78.PubMedCentralPubMed

163.

Kyrieleis HA, Löwik MM, Pronk I, Cruysberg HR, Kremer JA, Oyen WJ, van den Heuvel BL, Wetzels JF, Levtchenko EN. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol. 2009;4:1593–600.PubMedCentralPubMed

164.

Requião-Moura LR, Veras de S Freitas T, Franco MF, Pereira AB, Mastroianni-Kirsztajn G. Should adolescents with glomerulopathies be treated as children or adults? Nephron Clin Pract. 2008;109:c161–7.PubMed

165.

Simmonds J, Grundy N, Trompeter R, Tullus K. Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome. Arch Dis Child. 2010;95:146–9.PubMed

166.

Emma F, Sesto A, Rizzoni G. Long-term linear growth of children with severe steroid-responsive nephrotic syndrome. Pediatr Nephrol. 2003;18:783–8.PubMed

167.

Takahashi T, Inaba S, Oshima T, Ishihara S, Toyoda Y, Kurose K, Takai R, Yoshida A, Okada T, Takada T, Yanagihara T. Growth of children with idiopathic nephrotic syndrome. The effect of steroid therapy. J Jpn Pediatr Soc. 1991;95:1850–5 (article in Japanese).

168.

Kaku Y, Ohtsuka Y, Komatsu Y, Ohta T, Nagai T, Kaito H, Kondo S, Ikezumi Y, Tanaka S, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, Saito H, Fujinaga S, Hamasaki Y, Chikamoto H, Ishikura K, Iijima K. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy, clinical and experimental nephrology. Clin Exp Nephrol. doi:10.1007/s10157-014-1031-9.

169.

Kranz B, Vester U, Büscher R, Wingen AM, Hoyer PF. Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years. Pediatr Nephrol. 2008;23:581–6.PubMedCentralPubMed

170.

Drube J, Geerlings C, Taylor R, Mengel M, Ehrich JH. Fifteen-year remission of a steroid-resistant nephrotic syndrome sustained by cyclosporine A. Pediatr Nephrol. 2007;22:600–2.PubMed

171.

Ghiggeri GM, Catarsi P, Scolari F, Caridi G, Bertelli R, Carrea A, Sanna-Cherchi S, Emma F, Allegri L, Cancarini G, Rizzoni GF, Perfumo F. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. Clin Ther. 2004;26:1411–8.PubMed

172.

Chishti AS, Sorof JM, Brewer ED, Kale AS. Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am J Kidney Dis. 2001;38:754–60.PubMed

173.

Hino S, Takemura T, Okada M, Murakami K, Yagi K, Fukushima K, Yoshioka K. Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. Am J Kidney Dis. 1998;31:932–9.PubMed

174.

Gregory MJ, Smoyer WE, Sedman A, Kershaw DB, Valentini RP, Johnson K, Bunchman TE. Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J Am Soc Nephrol. 1996;7:543–9.PubMed

175.

Neuhaus TJ, Burger HR, Klingler M, Fanconi A, Leumann EP. Long-term low-dose cyclosporin A in steroid dependent nephrotic syndrome of childhood. Eur J Pediatr. 1992;151:775–8.PubMed

176.

Melocoton TL, Kamil ES, Cohen AH, Fine RN. Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Am J Kidney Dis. 1991;18:583–8.PubMed

177.

Fujinaga S, Ohtomo Y, Akashi S, Kaneko K. Chronic cyclosporine-induced nephropathy in children with nephrotic syndrome. Japanese Journal of Pediatric Nephrology. 2004;17:66–71 (article in Japanese).

178.

Bogdanović R, Banićević M, Cvorić A. Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study. Pediatr Nephrol. 1990;4:451–4.PubMed

179.

Jones DP, Stapleton FB, Roy S 3rd, Wyatt RJ. Beneficial effect of second courses of cytotoxic therapy in children with minimal change nephrotic syndrome. Pediatr Nephrol. 1988;2:291–5.PubMed

Titel: Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy
verfasst von: Kenji Ishikura
Shinsuke Matsumoto
Mayumi Sako
Kazushi Tsuruga
Koichi Nakanishi
Koichi Kamei
Hiroshi Saito
Shuichiro Fujinaga
Yuko Hamasaki
Hiroko Chikamoto
Yasufumi Ohtsuka
Yasuhiro Komatsu
Toshiyuki Ohta
Takuhito Nagai
Hiroshi Kaito
Shuji Kondo
Yohei Ikezumi
Seiji Tanaka
Yoshitsugu Kaku
Kazumoto Iijima
Publikationsdatum: 01.02.2015
Verlag: Springer Japan
Erschienen in: Clinical and Experimental Nephrology / Ausgabe 1/2015
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-014-1030-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

An AKI biomarker lipocalin 2 in the blood derives from the kidney in renal injury but from neutrophils in normal and infected conditions

A new cause of severe anemia in renal transplant recipients: watermelon stomach

Prevalence and incidence of chronic kidney disease stage G5 in Japan

Serum renalase is related to catecholamine levels and renal function

Hyperbaric area index calculated from ABPM elucidates the condition of CKD patients: the CKD-JAC study